Search clinical trials for: RC48-ADC and JS001

Total 2737 results

RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With JS001 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
RemeGen Co., Ltd.

Recruiting

To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)

Gastric Cancer

China
Peking University Cancer Hospital & Institute

Unknown

A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
Jinling Hospital, China

Recruiting

A Study of RC48-ADC Combined With JS001 For Postoperative Adjuvant Treatment of Upper Tract Urothelial Carcinoma (1)

Carcinoma | Upper Tract Urothelial Carcinoma | UTUC

China
Peking University
RemeGen Co., Ltd.

Recruiting

JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors

HER2-Positive Solid Tumors

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway

Metastatic Breast Cancer

China
RemeGen Co., Ltd.

Completed

Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors

Solid Tumors

China
Peking Union Medical College Hospital

Recruiting

Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Salivary Gland Tumors

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With HER2-Positive Advanced Malignant Solid Tumors

Solid Tumors

China
RemeGen Co., Ltd.

Not yet recruiting

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With Advanced Breast Cancer

Advanced Breast Cancer

China
Chinese PLA General Hospital

Recruiting

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Advanced Gastroesophageal Adenocarcinoma

China
Tianjin Medical University Cancer Institute and...
Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaborators

Not yet recruiting

An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cancer

Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder Cance
Shanxi Province Cancer Hospital
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Recruiting

A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma

China
Jiangsu Cancer Institute & Hospital

Not yet recruiting

RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2

Biliary Tract Cancer
RenJi Hospital

Recruiting

RC48-ADC in HER2-low Advanced Breast Cancer

Advanced Breast Cancer

China
RemeGen Co., Ltd.

Not yet recruiting

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Non-small Cell Lung Cancer

China
Fudan University

Recruiting

DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC

Renal Insufficiency | Solitary Kidney | Upper Urinary Tract Urothelial Carcinoma

China
West China Hospital
RemeGen Co., Ltd.

Not yet recruiting

RC48-ADC in Adjuvant/Salvage Treatment of HER2 Positive Non-muscle-invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

A Clinical Study of RC48-ADC Combined With Triplizumab For Treatment of Myometrial Invasive Bladder Cancer

Bladder Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

A Study Explore JS001+JS002 in Patients With Advanced Cancer

Advanced Cancer

China
Shanghai Junshi Bioscience Co., Ltd.
CTI Clinical Trial and Consulting Services; TopAlliance Biosciences, Inc.

Withdrawn

A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies

Malignancies | Previously Treated, Advanced
TopAlliance Biosciences
Shanghai Junshi Bioscience Co., Ltd.; CTI Clinical Trial and Consulting Services

Recruiting

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Metastatic Solid Tumor | Advanced Unresectable Solid Tumor

United States
Peking University Cancer Hospital & Institute

Not yet recruiting

Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer
RemeGen Co., Ltd.

Recruiting

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Cancer

China
Seagen Inc.

Recruiting

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Endometrial Neoplasms | Carcinoma, Squamous Cell of Head and Neck

United States, Australia, Canada
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma

Urothelial Carcinoma | HER2-expressing

China
RenJi Hospital

Recruiting

RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC

Radiotherapy | Muscle Invasive Bladder Cancer | PD-1 | HER2 Expression | Antibody-drug Conjugates

China
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
RenJi Hospital

Recruiting

RC48-ADC in Breast Cancer

Breast Cancer

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Gastric Cancer

China
RemeGen Co., Ltd.

Recruiting

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Solid Tumor

China
RemeGen Co., Ltd.

Active, not recruiting

A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Breast Neoplasms | Breast Diseases | HER2-positive Breast Cancer | Capecitabine | HER2 Positive Breast Carcinoma | HER2-positive Advanced Breast With Liver Metastases

China
Xijing Hospital

Not yet recruiting

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer

Cervical Cancer

China
Cancer Institute and Hospital, Chinese Academy...
Shanxi Province Cancer Hospital

Recruiting

A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer

Muscle Invasive Bladder Carcinoma

China
Sun Yat-sen University

Not yet recruiting

Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | RC48 | Disitamab Vedotin

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Gastric Cancer | HER2 Overexpressing Gastric Carcinoma

China
Fudan University

Active, not recruiting

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Triple Negative Breast Cancer

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)

Advanced Melanoma | Melanoma, Stage II | HER2-positive

China
RemeGen Co., Ltd.

Active, not recruiting

A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer

Biliary Tract Cancer

China
RemeGen Co., Ltd.

Recruiting

RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects

NMIBC

China
RemeGen Co., Ltd.

Completed

A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
Seagen Inc.
RemeGen Co., Ltd.

Recruiting

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Stomach Neoplasms | Breast Neoplasms | Triple Negative Breast Neoplasms | Gastroesophageal Junction Adenocarcinoma | HER2 Positive Breast Neoplasms | HER2 Low Breast Neoplasms

United States
RemeGen Co., Ltd.

Completed

A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer

Advanced Cancer | Urothelial Carcinoma

China
RemeGen Co., Ltd.

Recruiting

A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies

Gynecological Malignancy

China
RemeGen Co., Ltd.

Recruiting

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

Nasopharyngeal Carcinoma | Head and Neck Squamous Cell Carcinom

China
RemeGen Co., Ltd.

Completed

A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Urothelial Carcinoma

China
Xu jianmin

Unknown

A Study for PD-1 Antibody JS001 in MSI-H Advanced or Recurrent Colorectal Cancer

Colorectal Cancer

China

3

Subscribe